AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ubiquitin-protein ligase E3C

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q15386

UPID:

UBE3C_HUMAN

Alternative names:

HECT-type ubiquitin transferase E3C; Homologous to E6AP carboxyl terminus homologous protein 2; RTA-associated ubiquitin ligase

Alternative UPACC:

Q15386; A4D235; A6NCP3; Q8TC15; Q96CR4; Q9UDU3

Background:

Ubiquitin-protein ligase E3C, known for its roles in protein ubiquitination, catalyzes 'Lys-29'- and 'Lys-48'-linked polyubiquitin chains. It interacts with the proteasome to promote ubiquitin chain elongation on substrates, facilitating their degradation. This protein also regulates autophagy and type I interferon response through targeted ubiquitination, showcasing its pivotal role in cellular processes.

Therapeutic significance:

Understanding the role of Ubiquitin-protein ligase E3C could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.